Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$9.99
-2.7%
$9.46
$3.75
$11.54
$160.04M2.7355,815 shs29,132 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$2.23
-4.7%
$1.90
$1.64
$12.51
$744.67M0.859.49 million shs14.74 million shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$0.62
+1.6%
$0.46
$0.35
$2.15
$625.34M1.8231.33 million shs28.80 million shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$15.27
-0.9%
$10.37
$3.42
$17.00
$705.49M1.021.11 million shs1.20 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
0.00%-7.59%+11.74%+142.48%+998,999,900.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%+19.25%+9.31%-27.00%-75.06%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.00%+7.03%+62.09%+38.07%-67.30%
Urogen Pharma stock logo
URGN
Urogen Pharma
0.00%+7.23%+2.69%+57.91%-9.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
1.0681 of 5 stars
3.50.00.00.00.00.80.0
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.7264 of 5 stars
4.21.00.04.22.94.21.3
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
1.7069 of 5 stars
3.11.00.00.02.50.01.3
Urogen Pharma stock logo
URGN
Urogen Pharma
4.3434 of 5 stars
4.52.00.04.51.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$20.00100.20% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.33
Hold$12.22448.08% Upside
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.25
Hold$1.92208.49% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.86115.17% Upside

Current Analyst Ratings Breakdown

Latest ACOG, IOVA, URGN, and TLRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
7/7/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/16/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$50.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$16.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Buy$31.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $30.00
6/12/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/3/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/A$2.59 per shareN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$164.07M4.54N/AN/A$2.33 per share0.96
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$788.94M0.79N/AN/A$4.14 per share0.15
Urogen Pharma stock logo
URGN
Urogen Pharma
$90.40M7.80N/AN/A($0.21) per share-72.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$14.64M-$1.20N/AN/AN/A-65.83%-48.21%8/11/2025 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%7/28/2025 (Estimated)
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)

Latest ACOG, IOVA, URGN, and TLRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.29N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.85N/AN/AN/A$23.06 millionN/A
8/11/2025Q2 2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.84N/AN/AN/A$2.32 millionN/A
7/28/2025Q4 2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.03N/AN/AN/A$250.41 millionN/A
5/15/2025Q1 2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million
5/12/2025Q1 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
17.14
16.83
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.18
3.64
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.12
2.62
1.61
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
5.65
5.47

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
14.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
10.30%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.60%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A16.02 million13.78 millionN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million299.54 millionOptionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2,6501.01 billion1.00 billionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.20 million44.03 millionOptionable

Recent News About These Companies

Urogen Pharma's (URGN) Buy Rating Reiterated at HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$9.99 -0.28 (-2.73%)
As of 07/18/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$2.23 -0.11 (-4.70%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.24 +0.00 (+0.22%)
As of 07/18/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$0.62 +0.01 (+1.64%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.63 +0.01 (+1.72%)
As of 07/18/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$15.27 -0.14 (-0.91%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$15.18 -0.09 (-0.62%)
As of 07/18/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.